Business
Coloplast A/S - Announcement no. 07/2025 - Coloplast announces new financial ambition towards 2030
In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in line with or above revenue growth over the period and Return on Invested Capital (ROIC) of more than 20% in FY 2029/30. At its Capital Markets Day on 2 September 2025, Coloplast will present a new 5-year strategy, Impact4. In relation to the strategic update, Coloplast is providing a new long-term fin
About this update from Coloplast A/s Class B
In relation to the launch of Coloplast’s new 5-year strategy, Impact4, the company announces a new financial ambition with organic revenue CAGR of 7-8% until FY 2029/30, growth in absolute EBIT* in line with or above revenue growth over the period and Return on Invested Capital (ROIC) of more than 20% in FY 2029/30. At its Capital Markets Day on 2 September 2025, Coloplast will present a new 5-year strategy, Impact4 . In relation to the strategic update, Coloplast is providing a new long-term financial ambition towards 2030. Impact4 financial ambition: Coloplast is committed to accelerating shareholder value creation by delivering organic revenue growth above the market, strong growth in EBIT, improvement in ROIC and strong cash flow generation. From the base financial year of 2024/25, Coloplast aims to deliver the following long-term financial ambitions: The new financial ambition includes the following key assumptions: Additional financial assumptions for the period include: To participate in the plenary session of the Capital Markets Day 2025 virtually, please follow the link here: Coloplast Capital Markets Day 2025 . All material from the Capital Markets Day will be made available during the day on Coloplast’s website: Investors . * In constant currencies; before special items Forward-looking statements The forward-looking statements in this announcement, including revenue and earnings guidance, do not constitute a guarantee of future results and are subject to risk, uncertainty and assumptions, the consequences of which are difficult to predict. The forward-looking statements are based on our current expectations, estimates and assumptions and are provided on the basis of information available to us at the present time. Major fluctuations in the exchange rates of key currencies, significant changes in the healthcare sector or major developments in the global economy may impact our ability to achieve the defined long-term targets and meet our guidance. This may impact our company’s financial results. Contacts: Investors: Aleksandra Dimovska Vice President, Investor Relations Tel. +45 4911 1800 / +45 4911 2458 Email: [email protected] Kristine Husted Munk Senior Director, Investor Relations Tel. +45 4911 1800 / +45 4911 3266 Email: [email protected] Simone Dyrby Helvind Senior Manager, Investor Relations Tel. +45 4911 1800 / +45 4911 2981 Email: [email protected] Media: Peter Mønster Senior Media Relations Manager Tel. +45 4911 2623 Email: [email protected] Address Coloplast A/S Holtedam 1 DK-3050 Humlebaek Denmark Company reg. (CVR) no. 69749917 Website www.coloplast.com This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Attachment
View stock analysis, news, and events for Coloplast A/s Class B